Pre-clinical studies in colorectal cancer, B cell lymphoma, thyroid cancer, refractory lymphoma, and multiple myeloma have shown that CUDC-907 significantly inhibits both the PI3K pathway and different HDAC enzymes, to inhibit cancer proliferation and growth [33,34]. The gene discussed is HDAC9; the disease is plasma cell myeloma.